Viewpoint discusses the need for preclinical evidence on caffeine's safety and efficacy before trials.
This Viewpoint describes the need for more preclinical work to increase confidence that caffeine is safe and beneficial as a postnatal treatment for hypoxic-ischemic encephalopathy before clinical trials are conducted.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: